Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?

23 Dec 2019

Abstract excerpt

Human papillomaviruses (HPVs) are the most common sexually transmitted infections worldwide. Ninety percent of infected individuals clear the infection within two years; however, in the remaining 10% of infected individuals, the infection(s) persists and ultimately leads to cancers (anogenital cancers and head and neck cancers) and genital warts. Fortunately, three prophylactic vaccines have been approved to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacteriophages and microbial interactions
Share to Cervical Cancer and HPV Research
Share to Hepatitis B Virus Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31877975
DOI: 10.3390/v12010018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?PMID 31877975Read ↗

Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated DiseasesSemantic proximity Read ↗

A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2Semantic proximity Read ↗

RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine CandidatesSemantic proximity Read ↗

In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccineSemantic proximity Read ↗

Potential of Recombinant Chimeric HPV16 L1/L2 VLPs Produced by Distinct Cell Lineages Such as Prophylactic Nanovaccine and Therapeutic Drug NanocarriersSemantic proximity Read ↗

RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human CancerSemantic proximity Read ↗

Diseases caused by human papillomaviruses (HPV)Semantic proximity Read ↗

Developments in L2-based human papillomavirus (HPV) vaccinesSemantic proximity Read ↗

L2 epitope presenting virus-like particles as broad- spectrum vaccine candidates targeting genus beta human papillomavirusesSemantic proximity Read ↗

Papillomavirus Prophylactic Vaccines: Established Successes, New ApproachesSemantic proximity Read ↗

The use of hybrid virus‐like particles to enhance the immunogenicity of a broadly protective HPV vaccineSemantic proximity Read ↗

Cervarix™ – a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.